《中国医药集团有限公司（SINOPHARM）2023年年度报告（英文版）（243页）.pdf》由会员分享，可在线阅读，更多相关《中国医药集团有限公司（SINOPHARM）2023年年度报告（英文版）（243页）.pdf（243页珍藏版）》请在三个皮匠报告上搜索。

1、*The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name“Sinopharm Group Co.Ltd.”.2023Annual Report Annual Report 2023SINOPHARM GROUP CO.LTD.Sinopharm Group Building,No.385,East Longhua Road,Huangpu District,Shanghai 20

2、0023,the PRCThe Company was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited(stock code:01099.HK)in September 2009,is a core subsidiary of China National Pharmaceutical Group Co.,Ltd.and a top-rank wholesaler and retailer of pharmaceutical and healthcare products and

3、 medical devices,and a leading supply-chain service provider in the PRC.The Group is mainly engaged in pharmaceutical products and medical device distribution business.Leveraging on its nationwide distribution and delivery network,the Group provides comprehensive distribution,delivery and other valu

4、e-added services to domestic and foreign manufacturers and suppliers of pharmaceutical products,medical devices and consumables and other healthcare products,and also to downstream customers including hospitals,other distributors,retail drug stores and primary health services institutions.Meanwhile,

5、the Group manages its network of retail drug stores chain in major cities of China via direct operations and franchises to sell pharmaceutical and healthcare products to end customers.It has become a leader in Chinas pharmaceutical retail industry.Besides,the Group is also engaged in the production

6、and sale of pharmaceutical products,chemical reagents and laboratory supplies,and actively engaged in the innovation of pharmaceutical,medical services and other health-related industries,to explore the synergistic development of its diversified businesses.Taking advantage of its superior economies